Peter C. Wulff serves as an independent board member of NKore Therapeutics. He is a seasoned financial executive with more than 40 years of experience in capital formation, financial strategy, and operational scale-up for emerging and growth-stage life sciences and medical technology companies across public and private markets.

Mr. Wulff has led numerous equity, venture, and debt financings and brings deep expertise in supporting companies through key value-inflection points, including commercialization readiness, capital raise and restructuring, cross-border expansion, and public-company preparation. He currently serves as Chief Financial Officer and Corporate Secretary of Glucotrack, Inc. Previously, he held senior financial leadership roles at Biological Dynamics and JenaValve Technology, where he was instrumental in executing significant capital raises, relocating and integrating U.S. and European operations, advancing clinical and manufacturing capabilities, and positioning the companies for potential IPO and strategic transactions.

Mr. Wulff has maintained a professional relationship with Dr. Aaron U. Levy, Chairman and CEO of NKore, for over 18 years, advising each other on strategy, capital formation, and execution across multiple life sciences, genomics, and medical device ventures.

Earlier in his career, Mr. Wulff served as a senior financial executive at several medical technology companies, including Alphatec Spine Holdings, Artes Medical, CryoCor, and Pure Biosciences. He holds an MBA in Finance and a bachelor’s degree from Indiana University and is fluent in Dutch and German.